Evidence map›Paper›PMID 32081369›Full record

ArticleTranslational oncology2020

Corrigendum to High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype12 [Translational Oncology Volume 12, Issue 2, February 2019, Pages 256-268].

N Golob-Schwarzl, K Bettermann, A K Mehta, S M Kessler, J Unterluggauer, S Krassnig, K Kojima, X Chen, Y Hoshida, N M Bardeesy and 18 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

N Golob-SchwarzlInstitute of Pathology, Medical University of Graz, Graz, Austria; Center for Biomarker Research in Medicine, Graz, Austria.
K BettermannInstitute of Pathology, Medical University of Graz, Graz, Austria.
A K MehtaInstitute of Pathology, Medical University of Graz, Graz, Austria; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
S M KesslerInstitute of Pathology, Medical University of Graz, Graz, Austria; Department of Pharmacy, Pharmaceutical Biology, Saarland University, Saarbrücken, Germany.
J UnterluggauerInstitute of Pathology, Medical University of Graz, Graz, Austria.
S KrassnigInstitute of Pathology, Medical University of Graz, Graz, Austria.
K KojimaLiver Tumor Translational Research Program, University of Texas Southwestern Medical Center, Dallas, USA.
X ChenLiver Tumor Translational Research Program, University of Texas Southwestern Medical Center, Dallas, USA.
Y HoshidaLiver Tumor Translational Research Program, University of Texas Southwestern Medical Center, Dallas, USA.
N M BardeesyCenter for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
H MüllerInstitute of Pathology, Medical University of Graz, Graz, Austria.
V SvendovaInstitute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.
M G SchimekInstitute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.
C DiwokyInstitute of Medical Engineering, Graz University of Technology, Graz, Austria; Institute of Molecular Biosciences, University of Graz, Graz, Austria.
A LipfertInstitute of Medical Engineering, Graz University of Technology, Graz, Austria.
V MahajanInstitute of Pathology, Medical University of Graz, Graz, Austria.
C StumptnerInstitute of Pathology, Medical University of Graz, Graz, Austria.
A ThüringerInstitute of Pathology, Medical University of Graz, Graz, Austria.
L F FröhlichInstitute of Pathology, Medical University of Graz, Graz, Austria; AG VABOS, Department of Cranio-Maxillofacial Surgery, Univerity of Muenster, Germany.
T StojakovicClinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria.
K P R NilssonDepartment of Chemistry, Linköping University, Linköping, Sweden.
T KolbeBiomodels Austria (Biat), University of Veterinary Medicine Vienna, Vienna, Austria; Department IFA-Tulln, University for Natural Resources and Applied Life Sciences Vienna, Vienna, Austria.
T RülickeInstitute of Laboratory Animal Science, University of Veterinary Medicine Vienna, Vienna, Austria.
T M MaginInstitute of Biology, University of Leipzig, Leipzig, Germany.
P StrnadDepartment of Internal Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
A K KiemerCenter for Biomarker Research in Medicine, Graz, Austria.
R MorigglInstitute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, Vienna, Austria; Ludwig Bolzmann Institute of Cancer Research, Vienna, Austria; Medical University Vienna, Vienna, Austria.
Johannes HaybaeckInstitute of Pathology, Medical University of Graz, Graz, Austria; Department of Pathology, Medical Faculty, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany. Electronic address: Johannes.haybaeck@med.ovgu.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID32081369
PMCPMC7031098

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.